AngioDynamics (ANGO) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies USD Explore free reports

AngioDynamics (ANGO) overview

AngioDynamics (ANGO) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 320m and operating profit of USD -39.9m; the year-end share price was 11.48 USD and market capitalisation was USD 479m. AngioDynamics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AngioDynamics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 171mFY 2026
Share price11.48 USDFY 2026 year end
RevenueUSD 320mFY 2026
Operating profitUSD -39.9mFY 2026
Net earningsUSD -36.7mFY 2026
Market capitalisationUSD 479mFY 2026 year end

About AngioDynamics

AngioDynamics designs, manufactures, and sells medical products and technologies used by clinicians treating cardiovascular disease and cancer. Its offerings include the Auryon atherectomy system for peripheral arterial disease, mechanical thrombectomy systems, venous drainage cannulas and circuits, and catheter-directed thrombolytic devices. The company serves clinicians and patients through products intended to support procedures addressing vascular conditions and cancer diagnoses.

Generate the AngioDynamics report

AngioDynamics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for AngioDynamics and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on AngioDynamics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.